Athenex Announces Positive Results of Special Stockholder Meeting
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Athenex, Inc. (NASDAQ: ATNX) held a Special Stockholder Meeting on November 22, 2022, where shareholders approved all three proposals presented. The proposals included increasing the total number of authorized shares of common stock, authorizing a reverse stock split aimed at raising the stock price and ensuring Nasdaq compliance, and increasing share availability under the 2017 Omnibus Incentive Plan. Detailed voting results will be provided in an upcoming Current Report on Form 8-K.
Positive
- Shareholders approved an increase in the total number of authorized shares, enhancing financial flexibility.
- Approval of a reverse stock split aims to increase the stock price and help regain Nasdaq compliance.
- Increase in shares available under the Omnibus Incentive Plan may attract and retain talent.
Negative
- None.
Details
News Market Reaction – ATNX
The recorded move for ATNX in the trading session of this news was +3.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Shareholders voted in favor of all three proposals submitted before the Special Stockholder Meeting
BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the results of its special meeting of stockholders (the “Special Meeting”), held as a virtual meeting on November 22, 2022.
Athenex shareholders have approved all three proposals put before them today at the Special Meeting, including: (1) to effect an increase in the total number of authorized shares of common stock of the Company, (2) to authorize a reverse stock split of the Company’s common stock, which is intended to increase the per share price of the common stock and enable the Company to regain compliance with the Nasdaq continued listing requirements, and (3) to increase the number of shares available for issuance under the Company's 2017 Omnibus Incentive Plan.
Further details on the voting results for each of the proposals put before the shareholders at the Special Meeting can be found in the Current Report on Form 8-K that Athenex intends to file with the Securities and Exchange Commission later today.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible, and tolerable treatments. For more information, please visit www.athenex.com.
Athenex Contacts
Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.